Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2023-02-21 17:14:38 UTC |
---|
HMDB ID | HMDB0000239 |
---|
Secondary Accession Numbers | - HMDB0002075
- HMDB00239
- HMDB02075
|
---|
Metabolite Identification |
---|
Common Name | Pyridoxine |
---|
Description | Pyridoxine, also known vitamin B6, is commonly found in food and is used as a dietary supplement. Pyridoxine is an essential nutrient, meaning the body cannot synthesize it, and it must be obtained from the diet. Sources in the diet include fruit, vegetables, and grain. Although pyridoxine and vitamin B6 are still frequently used as synonyms, especially by medical researchers, this practice is sometimes misleading (PMID: 2192605 ). Technically, pyridoxine is one of the compounds that can be called vitamin B6 or it is a member of the family of B6 vitamins. Healthy human blood levels of pyridoxine are 2.1 - 21.7 ng/mL. Pyridoxine is readily converted to pyridoxal phosphate which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids and aminolevulinic acid. Pyridoxine assists in the balancing of sodium and potassium as well as promoting red blood cell production. Therefore pyridoxine is required by the body to make amino acids, carbohydrates, and lipids. It is linked to cancer immunity and helps fight the formation of homocysteine. It has been suggested that pyridoxine might help children with learning difficulties, and may also prevent dandruff, eczema, and psoriasis. In addition, pyridoxine can help balance hormonal changes in women and aid in immune system. Lack of pyridoxine may cause anemia, nerve damage, seizures, skin problems, and sores in the mouth (Wikipedia ). Deficiency of pyridoxine, though rare because of widespread distribution in foods, leads to the development of peripheral neuritis in adults and affects the central nervous system in children (DOSE - 3rd edition). As a supplement pyridoxine is used to treat and prevent pyridoxine deficiency, sideroblastic anaemia, pyridoxine-dependent epilepsy, certain metabolic disorders, problems from isoniazid, and certain types of mushroom poisoning. Pyridoxine in combination with doxylamine is used as a treatment for morning sickness in pregnant women. |
---|
Structure | InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3 |
---|
Synonyms | Value | Source |
---|
2-Methyl-3-hydroxy-4,5-dihydroxymethylpyridine | ChEBI | 3-Hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine | ChEBI | 3-Hydroxy-4,5-dimethylol-alpha-picoline | ChEBI | 5-Hydroxy-6-methyl-3,4-pyridinedimethanol | ChEBI | Pyridoxol | ChEBI | Vitamin b6 | ChEBI | 3-Hydroxy-4,5-dimethylol-a-picoline | Generator | 3-Hydroxy-4,5-dimethylol-α-picoline | Generator | 2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine | HMDB | 2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine | HMDB | 2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine | HMDB | 3-Hydroxy-2-picoline-4,5-dimethanol | HMDB | Adermine | HMDB | Gravidox | HMDB | Hydoxin | HMDB | Piridossina | HMDB | Piridoxina | HMDB | Pyridoxin | HMDB | Pyridoxinum | HMDB | Pyridoxolum | HMDB | Pyridoxol hydrochloride | HMDB | Rodex | HMDB | Pyridoxine hydrochloride | HMDB |
|
---|
Chemical Formula | C8H11NO3 |
---|
Average Molecular Weight | 169.1778 |
---|
Monoisotopic Molecular Weight | 169.073893223 |
---|
IUPAC Name | 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol |
---|
Traditional Name | pyridoxine |
---|
CAS Registry Number | 65-23-6 |
---|
SMILES | CC1=C(O)C(CO)=C(CO)C=N1 |
---|
InChI Identifier | InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3 |
---|
InChI Key | LXNHXLLTXMVWPM-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as pyridoxines. These are pyridoxal derivatives in which the carbaldehyde group at position 2 of the pyridoxal moiety is replaced by a hydroxymethyl group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Pyridines and derivatives |
---|
Sub Class | Pyridoxines |
---|
Direct Parent | Pyridoxines |
---|
Alternative Parents | |
---|
Substituents | - Pyridoxine
- Methylpyridine
- Hydroxypyridine
- Heteroaromatic compound
- Azacycle
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Aromatic alcohol
- Primary alcohol
- Organooxygen compound
- Organonitrogen compound
- Alcohol
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | Biological locationRoute of exposureSourceEndogenousExogenousFood- Food (HMDB: HMDB0000239)
Animal originHerb and spiceVegetableFruitNutCereal and cereal productPulseGourdCoffee and coffee productSoyDishTeaBaking goodBeverageAquatic originEggConfectioneryMilk and milk productOther milk productFermented milkFermented milk productUnfermented milk- Milk (Other mammals) (FooDB: FOOD00690)
- Milk (Human) (FooDB: FOOD00666)
- Milk (Cow) (FooDB: FOOD00618)
- Cow milk, pasteurized, vitamin A + D added, 0% fat (FooDB: FOOD00889)
- Cow milk, pasteurized, vitamin A + D added, 1% fat (FooDB: FOOD00890)
- Cow milk, pasteurized, vitamin A + D added, 2% fat (FooDB: FOOD00891)
- Cow milk, pasteurized, vitamin D added, 3.25% fat (FooDB: FOOD00892)
Fat and oilCocoa and cocoa productBaby foodUnclassified food or beverageSnack Synthetic |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 159 - 162 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 79 mg/mL | Not Available | LogP | -0.77 | SANGSTER (1993) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Pyridoxine,1TMS,isomer #1 | CC1=NC=C(CO)C(CO)=C1O[Si](C)(C)C | 1731.9 | Semi standard non polar | 33892256 | Pyridoxine,1TMS,isomer #2 | CC1=NC=C(CO)C(CO[Si](C)(C)C)=C1O | 1831.3 | Semi standard non polar | 33892256 | Pyridoxine,1TMS,isomer #3 | CC1=NC=C(CO[Si](C)(C)C)C(CO)=C1O | 1795.3 | Semi standard non polar | 33892256 | Pyridoxine,2TMS,isomer #1 | CC1=NC=C(CO[Si](C)(C)C)C(CO)=C1O[Si](C)(C)C | 1743.1 | Semi standard non polar | 33892256 | Pyridoxine,2TMS,isomer #2 | CC1=NC=C(CO)C(CO[Si](C)(C)C)=C1O[Si](C)(C)C | 1812.4 | Semi standard non polar | 33892256 | Pyridoxine,2TMS,isomer #3 | CC1=NC=C(CO[Si](C)(C)C)C(CO[Si](C)(C)C)=C1O | 1839.6 | Semi standard non polar | 33892256 | Pyridoxine,3TMS,isomer #1 | CC1=NC=C(CO[Si](C)(C)C)C(CO[Si](C)(C)C)=C1O[Si](C)(C)C | 1891.9 | Semi standard non polar | 33892256 | Pyridoxine,1TBDMS,isomer #1 | CC1=NC=C(CO)C(CO)=C1O[Si](C)(C)C(C)(C)C | 2008.9 | Semi standard non polar | 33892256 | Pyridoxine,1TBDMS,isomer #2 | CC1=NC=C(CO)C(CO[Si](C)(C)C(C)(C)C)=C1O | 2076.8 | Semi standard non polar | 33892256 | Pyridoxine,1TBDMS,isomer #3 | CC1=NC=C(CO[Si](C)(C)C(C)(C)C)C(CO)=C1O | 2050.7 | Semi standard non polar | 33892256 | Pyridoxine,2TBDMS,isomer #1 | CC1=NC=C(CO[Si](C)(C)C(C)(C)C)C(CO)=C1O[Si](C)(C)C(C)(C)C | 2260.4 | Semi standard non polar | 33892256 | Pyridoxine,2TBDMS,isomer #2 | CC1=NC=C(CO)C(CO[Si](C)(C)C(C)(C)C)=C1O[Si](C)(C)C(C)(C)C | 2293.0 | Semi standard non polar | 33892256 | Pyridoxine,2TBDMS,isomer #3 | CC1=NC=C(CO[Si](C)(C)C(C)(C)C)C(CO[Si](C)(C)C(C)(C)C)=C1O | 2270.5 | Semi standard non polar | 33892256 | Pyridoxine,3TBDMS,isomer #1 | CC1=NC=C(CO[Si](C)(C)C(C)(C)C)C(CO[Si](C)(C)C(C)(C)C)=C1O[Si](C)(C)C(C)(C)C | 2543.7 | Semi standard non polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Pyridoxine GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS) | splash10-000t-0940000000-30b4702623a6d8fcb4bb | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Pyridoxine GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (Non-derivatized) | splash10-001j-0690000000-0581e2b42fa48c1ea498 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Pyridoxine GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS) | splash10-00di-9330000000-32929ff06762b9f5887f | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Pyridoxine GC-MS (3 TMS) | splash10-001i-0490000000-34a09ddbbb462aeb02a6 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Pyridoxine EI-B (Non-derivatized) | splash10-0f6x-9400000000-486db54a30b61c2eb9d4 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Pyridoxine GC-EI-TOF (Non-derivatized) | splash10-000t-0940000000-30b4702623a6d8fcb4bb | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Pyridoxine GC-EI-TOF (Non-derivatized) | splash10-001j-0690000000-0581e2b42fa48c1ea498 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Pyridoxine GC-EI-TOF (Non-derivatized) | splash10-00di-9330000000-32929ff06762b9f5887f | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Pyridoxine GC-MS (Non-derivatized) | splash10-001i-0490000000-34a09ddbbb462aeb02a6 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Pyridoxine GC-EI-TOF (Non-derivatized) | splash10-001j-0790000000-6f8f6e679e03f9119a65 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0f79-0900000000-0f727b3e23c2481951e8 | 2016-09-22 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (3 TMS) - 70eV, Positive | splash10-00di-7079000000-2f143e187cb8c078f936 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Pyridoxine GC-MS (TBDMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-1003-6900000000-1237eaf82dfadfd54d4b | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine Quattro_QQQ 10V, Positive-QTOF (Annotated) | splash10-0vi0-0900000000-bd0de86c072765a5caad | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine Quattro_QQQ 25V, Positive-QTOF (Annotated) | splash10-001i-3900000000-2018b406a3c75213b733 | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine Quattro_QQQ 40V, Positive-QTOF (Annotated) | splash10-0059-9200000000-e69bb531deb2a103a476 | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine EI-B (HITACHI M-80) , Positive-QTOF | splash10-0f6x-9400000000-77c43a946c4ae1abf3b9 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negative-QTOF | splash10-014i-0900000000-479d4492cc8d634fa366 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negative-QTOF | splash10-0udi-0900000000-486d6a4e5e1a731b7c54 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negative-QTOF | splash10-05fr-0900000000-4ef09ce9c04561a1085e | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negative-QTOF | splash10-0ab9-1900000000-3298adf6db36689d5d43 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negative-QTOF | splash10-0a6r-7900000000-6711954ee96f08344434 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positive-QTOF | splash10-00di-0900000000-234e90d43a7febd7a098 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positive-QTOF | splash10-0udi-0900000000-137080765c0035b45258 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positive-QTOF | splash10-001i-0900000000-882ee900a8bba08e2c7c | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positive-QTOF | splash10-003r-8900000000-e0e11797b63cea991d81 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positive-QTOF | splash10-0059-9100000000-c25384179219411af02c | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positive-QTOF | splash10-0ue9-0900000000-c0e149ce890192397b7f | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Negative-QTOF | splash10-0v4i-0900000000-f9f378af3d47ab006806 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QQ , negative-QTOF | splash10-014i-0900000000-479d4492cc8d634fa366 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QQ , negative-QTOF | splash10-0udi-0900000000-486d6a4e5e1a731b7c54 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pyridoxine LC-ESI-QQ , negative-QTOF | splash10-05fr-0900000000-4ef09ce9c04561a1085e | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pyridoxine 10V, Positive-QTOF | splash10-0uk9-0900000000-eab5b3411261744df750 | 2015-05-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pyridoxine 20V, Positive-QTOF | splash10-0ue9-0900000000-cc4dc8719602182ef1eb | 2015-05-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pyridoxine 40V, Positive-QTOF | splash10-001i-5900000000-1c2637733578fcdd7c6a | 2015-05-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pyridoxine 10V, Negative-QTOF | splash10-014i-0900000000-e89cc69d8b21012ff982 | 2015-05-27 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pyridoxine 20V, Negative-QTOF | splash10-059i-0900000000-0ad8d09e042015cb2e33 | 2015-05-27 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pyridoxine 40V, Negative-QTOF | splash10-0a4i-9500000000-577a3d87899ca47d539f | 2015-05-27 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, experimental) | 2012-12-04 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | 2012-12-05 | Wishart Lab | View Spectrum |
IR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M-H]-) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+) | 2023-02-03 | FELIX lab | View Spectrum |
|
---|
Disease References | Homozygous sickle cell disease |
---|
- van der Dijs FP, Schnog JJ, Brouwer DA, Velvis HJ, van den Berg GA, Bakker AJ, Duits AJ, Muskiet FD, Muskiet FA: Elevated homocysteine levels indicate suboptimal folate status in pediatric sickle cell patients. Am J Hematol. 1998 Nov;59(3):192-8. [PubMed:9798656 ]
| Epilepsy, early-onset, vitamin B6-dependent |
---|
- Darin N, Reid E, Prunetti L, Samuelsson L, Husain RA, Wilson M, El Yacoubi B, Footitt E, Chong WK, Wilson LC, Prunty H, Pope S, Heales S, Lascelles K, Champion M, Wassmer E, Veggiotti P, de Crecy-Lagard V, Mills PB, Clayton PT: Mutations in PROSC Disrupt Cellular Pyridoxal Phosphate Homeostasis and Cause Vitamin-B6-Dependent Epilepsy. Am J Hum Genet. 2016 Dec 1;99(6):1325-1337. doi: 10.1016/j.ajhg.2016.10.011. [PubMed:27912044 ]
| Crohn's disease |
---|
- Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
| Ulcerative colitis |
---|
- Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
| Colorectal cancer |
---|
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
| Eosinophilic esophagitis |
---|
- Slae, M., Huynh, H., Wishart, D.S. (2014). Analysis of 30 normal pediatric urine samples via NMR spectroscopy (unpublished work). NA.
|
|
---|
General References | - Amoroso A, Pirulli D, Florian F, Puzzer D, Boniotto M, Crovella S, Zezlina S, Spano A, Mazzola G, Savoldi S, Ferrettini C, Berutti S, Petrarulo M, Marangella M: AGXT gene mutations and their influence on clinical heterogeneity of type 1 primary hyperoxaluria. J Am Soc Nephrol. 2001 Oct;12(10):2072-9. [PubMed:11562405 ]
- Plecko B, Stockler-Ipsiroglu S, Paschke E, Erwa W, Struys EA, Jakobs C: Pipecolic acid elevation in plasma and cerebrospinal fluid of two patients with pyridoxine-dependent epilepsy. Ann Neurol. 2000 Jul;48(1):121-5. [PubMed:10894227 ]
- Henderson JM, Codner MA, Hollins B, Kutner MH, Merrill AH: The fasting B6 vitamer profile and response to a pyridoxine load in normal and cirrhotic subjects. Hepatology. 1986 May-Jun;6(3):464-71. [PubMed:3710434 ]
- Chiang EP, Selhub J, Bagley PJ, Dallal G, Roubenoff R: Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis. Arthritis Res Ther. 2005;7(6):R1404-11. Epub 2005 Oct 14. [PubMed:16277693 ]
- Manyam BV, Ferraro TN, Hare TA: Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington's disease. Brain Res. 1987 Apr 7;408(1-2):125-30. [PubMed:2885064 ]
- Temesvari P, Szilagyi I, Eck E, Boda D: Effects of an antenatal load of pyridoxine (vitamin B6) on the blood oxygen affinity and prolactin levels in newborn infants and their mothers. Acta Paediatr Scand. 1983 Jul;72(4):525-9. [PubMed:6624427 ]
- McCully KS: Homocysteine, vitamins, and prevention of vascular disease. Mil Med. 2004 Apr;169(4):325-9. [PubMed:15132238 ]
- Chen S, Ito M, Saijo T, Naito E, Kuroda Y: Molecular genetic analysis of pyridoxine-nonresponsive homocystinuric siblings with different blood methionine levels during the neonatal period. J Med Invest. 1999 Aug;46(3-4):186-91. [PubMed:10687314 ]
- Wasilewska A, Narkiewicz M, Rutkowski B, Lysiak-Szydlowska W: Is there any relationship between lipids and vitamin B levels in persons with elevated risk of atherosclerosis? Med Sci Monit. 2003 Mar;9(3):CR147-51. [PubMed:12640345 ]
- Kidd GS, Dimond R, Kark JA, Whorton N, Vigersky RA: The effects of pyridoxine on pituitary hormone secretion in amenorrhea-galactorrhea syndromes. J Clin Endocrinol Metab. 1982 Apr;54(4):872-5. [PubMed:6801073 ]
- Pirulli D, Marangella M, Amoroso A: Primary hyperoxaluria: genotype-phenotype correlation. J Nephrol. 2003 Mar-Apr;16(2):297-309. [PubMed:12768081 ]
- Tolis G, Laliberte R, Guyda H, Naftolin F: Ineffectiveness of pyridoxine (B6) to alter secretion of growth hormone and prolactin and absence of therapeutic effects on galactorrhea-amenorrhea syndromes. J Clin Endocrinol Metab. 1977 Jun;44(6):1197-9. [PubMed:559690 ]
- Esteve-Romero J, Capella-Peiro ME, Monferrer-Pons L, Gil-Agusti M: Micellar liquid chromatography in clinical chemistry: application to the monitorization of B6 vitamins. Clin Chim Acta. 2004 Oct;348(1-2):69-77. [PubMed:15369738 ]
|
---|